Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart). [1] Trimetazidine is described as the first cytoprotective anti- ischemic agent developed and marketed by Laboratoires Servier (France).

2022年2月11日 · Trimetazidine is a drug used to prevent or treat angina attacks—which is a type of chest pain caused by reduced blood flow to the heart—and other heart-related conditions. It works by increasing blood flow to the heart and limits rapid spikes in blood pressure.

2024年8月4日 · Trimetazidine (TMZ) is a medication used to treat heart-related conditions like angina. It helps metabolize fatty acids, which helps your body use oxygen.

2024年3月19日 · Trimetazidine inhibits fatty acid metabolism and stimulates the metabolism of glucose. It helps the body use oxygen, which relieves chest pain caused by blocked blood vessels. Trimetazidine comes in two strengths:

2022年12月4日 · What is trimetazidine? TMZ is an antianginal agent acting at the myocardial cell (heart cell) level and shown to be effective in minimizing angina attacks, nitrate usage and improving functional capacity. It is now available in a once-daily formulation.

2015年5月12日 · Trimetazidine is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.

Trimetazidine is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several—not yet fully understood—mechanisms of action. The best known trimetazidine mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) [1].

Trimetazidine is an antianginal medication approved in numerous countries for use in the symptomatic treatment of stable coronary artery disease and angina pectoris. Its main mechanism of action revolves around the inhibition of β-oxidation of free fatty acids in the myocardium, in addition to its antioxidant properties and inhibition of ...